CardiAQ Valve Technologies announced it successfully implanted its second-generation transcatheter mitral valve (TMVI) using the company’s newly added transapical delivery system. The transapical TMVI procedure was performed on an 88-year-old female suffering from severe mitral regurgitation (MR 4+) at The Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark.
